Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-97540 (CD19-targeted NEX-T CAR T) in Relapsed/Refractory B-cell NHL
NCT04231747Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- May 2020
- Primary completion
- Feb 2024
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of CC-986353 in B-cell non-Hodgkin lymphoma, sponsored by Celgene Corporation. Primary endpoint: Adverse Events (AEs) up to 2 years. Started May 2020; status: completed.
02
Drugs
CC-986353
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04231747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231747.